NS5A inhibitors in the treatment of hepatitis C

作者：Pawlotsky Jean Michel^*

来源：Journal of Hepatology, 2013, 59(2): 375-382.

DOI：10.1016/j.jhep.2013.03.030

• Hepatitis C virus
• NS5A inhibitor
• Daclatasvir
• Resistance

Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.

• 出版日期2013-8